CTLA4 and cancer: In anti-cancer immunotherapy, immune checkpoint blockers targeting PD-1/CTLA-4 have made a significant contribution, and these immune checkpoints are currently the most widely acknowledged biomarkers for predicting treatment response (Doroshow et al., 2021).